Overview

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

Status:
Recruiting

Trial end date:
2023-01-16

Target enrollment:

Participant gender:

Summary

This study aims to understand whether patients with MS can mount an immune response to SARS-CoV-2 mRNA vaccines when vaccinated either before initiation of ofatumumab treatment or at least 4 weeks after commencing ofatumumab treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Ofatumumab